Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies

Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Here, the safety and efficacy data from five Phase 2 studies of tofacitinib in patients with RA are summarized. Tofacitinib 1–30 mg twice daily was investigated, as monotherapy and in combination with metho...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Int J Rheum Dis
Auteurs principaux: Fleischmann, Roy, Kremer, Joel, Tanaka, Yoshiya, Gruben, David, Kanik, Keith, Koncz, Tamas, Krishnaswami, Sriram, Wallenstein, Gene, Wilkinson, Bethanie, Zwillich, Samuel H., Keystone, Edward
Format: Artigo
Langue:Inglês
Publié: John Wiley and Sons Inc. 2016
Sujets:
Review Articles
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5396326/
https://ncbi.nlm.nih.gov/pubmed/27451980
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1756-185X.12901
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires